Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids

Simons, F. Estelle R.; Persaud, M.P.; Gillespie, C. A.; Cheang, Mary; Shuckett, E. Paul

doi:10.1016/0140-6736(93)91541-s

Cited by 97 publications

(50 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…90 In a cross-sectional study of children taking inhaled beclomethasone or budesonide, no cataracts were found on slit-lamp examination, even in patients who had taken 2000 mg per day for more than 10 years. 91 …”

Section: Cataractsmentioning

confidence: 99%

Inhaled Glucocorticoids for Asthma

Barnes¹

1995

N Engl J Med

584

288

View full text Add to dashboard Cite

Section: Cataractsmentioning

confidence: 99%

Inhaled Glucocorticoids for Asthma

Barnes¹

1995

N Engl J Med

584

288

View full text Add to dashboard Cite

“…The association between systemic corticosteroid therapy and the development of posterior subcapsular cataracts was originally described by Black et al in adults in 1960 [7] . The prevalence of PSCC during oral corticosteroid therapy has been correlated with daily dose, cumulative dose, and duration of treatment [8] . Yilmaz et al [9] reports the prevalence of PSCC in asthmatic patients receiving corticosteroid therapy.…”

Section: Discussionmentioning

confidence: 99%

Back Ground Causes of Human Cataract Prevalence in the Non-Coastal Districts

Kuruvilla

Thomas²

2016

International Journal of Ophthalmic Research

View full text Add to dashboard Cite

“…Despite anecdotal reports [29,30] suggesting an increased risk of cataracts also with the use of ICSs, studies specifically designed to investigate the association between ICS use and the risk of developing cataract failed to find significant relationships [31][32][33]. These studies were, however, of limited sample size and mostly conducted in children in whom cataract is a rare event.…”

Section: Cataractmentioning

confidence: 99%

Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly

et al. 2015

View full text Add to dashboard Cite

Inhaled corticosteroids (ICSs) are widely used in the treatment of patients with chronic obstructive pulmonary diseases. However, high-dose regimens and longterm use of ICSs have the potential to cause a variety of local and systemic side effects such as candidiasis, cataracts, glaucoma, and osteoporosis. The use of ICSs can also be associated with the risk of bone fractures, diabetes mellitus and pneumonia. These ICS-related side effects are of particular importance in elderly patients due to the presence of comorbidities and age-related behavioral, cognitive, and psychological problems, which can all interact with inhaled treatment. We reviewed the available literature on the clinically relevant side effects of ICSs in the elderly to provide practical measures to properly monitor and manage the risk of ICSs in the geriatric population. Inspection of the mouth, monitoring of ocular pressure, and use of bone-protective drugs may be necessary in patients on prolonged ICS therapy. Above all, the use of the lowest possible ICS dose and a careful re-assessment of the inhalation procedure should be recommended. Taken together, these observations suggest that physicians should use ICSs appropriately for those patients in whom the benefit will outweigh the risk, especially chronic obstructive pulmonary disease (COPD) patients with previous frequent exacerbations. Given the paucity of information on the topic and the need to extrapolate the results from studies with broader age ranges, we strongly encourage the design of specifically tailored clinical studies in the elderly. Key PointsAsthma and chronic obstructive pulmonary disease (COPD) are inflammatory disorders of the airways. The pharmacological management of these chronic diseases is based on persistent and long-term use of inhaled corticosteroids (ICSs).Asthma and COPD are among the most common chronic diseases in clinical settings, and physicians are expected to diagnose and manage those diseases in the geriatric population on a daily basis. The management of chronic obstructive respiratory diseases in the geriatric population is complicated by the increased occurrence of comorbidities and associated treatment, and by age-associated physiological and structural changes of the lung.The chronic use of ICSs in the elderly is associated with the increased risk of local and systemic side effects such as candidiasis, cataract, glaucoma, diabetes mellitus, bone fractures, and pneumonia. Physicians should be aware of this in order to select those patients in whom the benefits will outweigh the risks.The online version of the original article can be found under

show abstract

Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids

Cited by 97 publications

References 13 publications

Inhaled Glucocorticoids for Asthma

Inhaled Glucocorticoids for Asthma

Back Ground Causes of Human Cataract Prevalence in the Non-Coastal Districts

Erratum to: Safety Considerations of Inhaled Corticosteroids in the Elderly

Contact Info

Product

Resources

About